SLS (SELLAS Life Sciences Group Inc.) stock: $8.42, $1.70B market cap, $138.3M cash, $1.56B EV, $1.84B fully diluted market cap. Lead program: Galinpepimut-S (Acute Myeloid Leukemia), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Memorial Sloan Kettering Cancer Center (license); 3D Medicines (license for development and commercialization in mainland China, Hong Kong, Macau and Taiwan)
Indications
Acute myeloid leukemia (maintenance after second complete remission)(Phase 3)
Status note Lead candidate galinpepimut-S. Ongoing open-label randomized Phase 3 REGAL study of GPS monotherapy vs best available treatment in AML maintenance after CR2.
Partnerships 3D Medicines (license for development and commercialization in mainland China, Hong Kong, Macau and Taiwan)
Status note Next-generation heptavalent immunotherapeutic at preclinical stage.
SLS009
Phase 2 · ActiveModality: small molecule (oral)
Aliases tambiciclib
Target CDK9
Partnerships GenFleet Therapeutics (exclusive license; worldwide except mainland China, Hong Kong, Macau and Taiwan); IMPACT-AML (agreement to sponsor and conduct a clinical study evaluating SLS009)
Indications
Acute myeloid leukemia(Phase 2)
Status note Highly selective CDK9 inhibitor. Randomized Phase 2 trial in newly diagnosed first-line AML in combination with venetoclax and azacitidine ongoing, with enrollment begun in Q1 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.